# Predictive properties of brain-derived neurotrophic factor in rTMS - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0900 - Language: en - Last updated: not specified - Page title: Predictive properties of brain-derived neurotrophic factor in rTMS | WCP 2026 Summary > Peripheral serum BDNF levels did not predict response to rTMS in major depressive disorder and did not change with rTMS treatment. This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0900) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0900 E-PosterNeuromodulationPost hoc analysis # Predictive properties of brain-derived neurotrophic factor in rTMS PREDICTIVE PROPERTIES OF BRAIN DERIVED NEUROTROPHIC FACTOR IN RTMS Presenter: Marcus Anderson Country: Sweden Institution: Uppsala University, Department of Medical Sciences, Clinical Psychiatry Peripheral serum BDNF levels did not predict response to rTMS in major depressive disorder and did not change with rTMS treatment. The study aimed to investigate the predictive value of peripherally measured serum brain-derived neurotrophic factor (BDNF) in patients receiving repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder (MDD), and whether BDNF was affected by treatment. A post hoc analysis pooled patients receiving routine care and clinical trial participants at the Brain Stimulation Unit of Uppsala University Hospital; a total of 143 individuals were evaluated, comprising clinical patients (n=97, mean age 35, standard deviation (SD) 12, DLPFC target), randomized controlled trial participants (n=38, age 30, SD 10, DMPFC target, iTBS), and an adolescent group (Teen-TMS, n=8, age 16, SD 1). The pooled sample included 64 men and 79 women, with a reported median baseline serum BDNF level of 12.5 ng/mL (interquartile range (IQR) 9.1) and a mean baseline MADRS-S score of 32.6 (SD 7.6). Blood samples were collected from all participants before treatment and only from randomized trial participants after treatment. No significant association was found between baseline serum BDNF levels and changes in MADRS-S scores: r=-0.01 (p=0.903) in clinical patients, r=0.16 (p=0.345) in randomized trial participants, r=-0.07 (p=0.867) in adolescents, and r=-0.02 (p=0.799) across all participants. Active iTBS applied over the DMPFC did not change BDNF concentrations compared with sham iTBS (n=38, F=0.701, p=0.407). The authors concluded that BDNF had no predictive value in rTMS treatment for MDD and did not change as a result of treatment; this finding does not support the use of serum BDNF as a biomarker for patient selection in clinical practice. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2014) How to cite this study APA 7: Anderson, M., et al. (2026, September 23-26). Predictive properties of brain derived neurotrophic factor in rtms [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2014 Vancouver: Anderson M, et al. Predictive properties of brain derived neurotrophic factor in rtms [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2014 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Kumar oynama bozukluğunda teta patlama uyarımının klinik etkinliği ve plasebo etkileri: başlangıçtaki anksiyete ve depresyonun rolü](https://alisanburak.com/en/wcp-2026-posterler/ev0055) - [Transkraniyal darbe uyarımı (TPS) Alzheimer hastalığı olan hastalarda uygun bir ek tedavi mi?](https://alisanburak.com/en/wcp-2026-posterler/ev0407) - [Demansta tedaviye dirençli ajitasyonda elektrokonvulsif tedavi: anlatısal derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0414) - [Elektrokonvulsif tedavi sonrası bilişsel değişimin nöroimmün ve psikolojik mekanizmaları: boylamsal MITO-ECT çalışmasının ön sonuçları](https://alisanburak.com/en/wcp-2026-posterler/ev0825) - [Yetişkin tedaviye dirençli depresyon hastalarında DEHB belirtilerini iyileştiren güçlendirilmiş tDCS'nin klinik ve görüntüleme mekanizmaları](https://alisanburak.com/en/wcp-2026-posterler/ev0851) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0900 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim